Close

Peptide EEY

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Repeated rounds of sorting allowed expansion of HLA-B∗4405-positive cells expressing a ligand that bound LC13 TCR. Peptide insert sequences were obtained from 36 positive clones with 30 of these encoding the peptide EEYLKAWTF. Searching the human proteome for analogs of the EEYLKAWTF "mimotope" peptide identified two high-scoring matches (expect values of 283 and 65, respectively), each of 9 residues (EESLKDWYF and EEYLQAFTY) and therefore representing a potential natural "allotope." These peptides shared 66% (6/9 identical residues) with the mimotope and possessed the P2E, P9Y/F anchor residues, features of B44-binding peptides. The peptide EESLKDWYF is derived from an ATPase but little is known about its physiologic role and expression. The peptide EEYLQAFTY is derived from an ATP binding cassette protein ABCD3 involved in transport of fatty acids into the peroxisome.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC0892 Human anti-Peptide EEY T cell receptor (LC13), pCDTCR1 LC13 Human EEYLKAWTF HLA-B*44:05 Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.